drugset
drugset / Trial / NCT00635232

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

NCT00635232 ↗

Phase 2 Completed 261 enrolled Ligand Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to learn which doses of PS433540 should be given to patients with high blood pressure to lower their blood pressure. This study will also examine how safe PS433540 is when taken by patients with high blood pressure. Approximately 720 patients will be evaluated so that about 375 patients will be entered into the treatment phase of the study and be given PS433540.

Timeline

Start
2008-03
Primary completion
2008-11
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Irbesartan Small molecule 300 mg —
Subject Sparsentan Small molecule 200 mg —
Subject Sparsentan Small molecule 400 mg —
Subject Sparsentan Small molecule 800 mg —

Indications

hypertensive disorder